This Australian biotech company successfully treated arthritis in a trial and …

This Australian biotech company successfully treated arthritis in a trial and …

The company announced the first results a trial giving 48 rheumatoid arthritis patients an intravenous infusion of Mesoblast's proprietary Mesenchymal Precursor Cell product. The treatment resulted in early and sustained clinical responses. A short

(Visited 1 times, 1 visits today)
4
Like
Save

Comments

Comments are disabled for this post.